Compare $APRE vs $SKYE | Chartloom

Compare

$APRE vs $SKYE

Aprea Therapeutics Inc · Skye Bioscience Inc

APRE

Aprea Therapeutics Inc

SKYE

Skye Bioscience Inc

Compare $APRE vs $SKYE

Comparing Aprea Therapeutics Inc and Skye Bioscience Inc

APREAprea Therapeutics Inc

SKYESkye Bioscience Inc

APREAprea Therapeutics Inc

Market cap

$7M

P/E (TTM)

—

Forward P/E (NTM)

—

Forward P/S (NTM)

—

Rev growth (TTM)

-99.4%

YTD performance

-29.1%

52W performance

-57.8%

FCF yield

-162.8%

SKYESkye Bioscience Inc

Market cap

$59M

P/E (TTM)

—

Forward P/E (NTM)

—

Forward P/S (NTM)

—

Rev growth (TTM)

—

YTD performance

-75.9%

52W performance

-87.7%

FCF yield

-65.4%

Add ticker

Add up to 1 more ticker to compare

Relative performance

Each ticker starts at 100. 110 means +10% from the start of this window — not a $110 share price.

APRE

SKYE

Detailed metrics comparison

APRE

Aprea Therapeutics Inc

SKYE

Skye Bioscience Inc

Market Cap

APRE$7M

SKYE$59M

Enterprise Value

APRE$-34M

SKYE$51M

Price

APRE$0.60

SKYE$1.69

P/E Ratio

APREN/A

SKYEN/A

P/S Ratio

APRE1,438.94x

SKYE26.57x

EV/Sales

APRE-6,490.56x

SKYE0.00x

EV/EBITDA

APRE0.00x

SKYE0.00x

P/B Ratio

APRE0.22x

SKYE0.83x

P/FCF Ratio

APREN/A

SKYEN/A

EV/FCF

APRE2.77x

SKYE-1.31x

PEG Ratio

APREN/A

SKYEN/A

Forward P/E (NTM)

APREN/A

SKYEN/A

Forward P/S (NTM)

APREN/A

SKYEN/A

Revenue (TTM)

APRE$5K

SKYE$0

Revenue Growth (YoY)

APRE-99.4%

SKYEN/A

Forward Rev Growth

APRE445.8%

SKYE307.4%

Gross Margin (TTM)

APRE0.0%

SKYE39.3%

Operating Margin (TTM)

APRE0.0%

SKYE0.0%

EBITDA Margin (TTM)

APRE-253869.2%

SKYE0.0%

Net Margin (TTM)

APRE-236676.9%

SKYE0.0%

FCF Margin (TTM)

APRE-234296.2%

SKYEN/A

Net Income (TTM)

APRE$-12M

SKYE$-50M

FCF (TTM)

APRE$-12M

SKYE$-39M

EPS (TTM)

APRE-$0.23

SKYE-$10.18

ROE (TTM)

APRE-4630.0%

SKYE-21727.0%

ROA (TTM)

APRE-4097.0%

SKYE-20179.0%

ROIC (TTM)

APRE-4630.0%

SKYE-21675.0%

Cash

APRE$41M

SKYE$9M

Debt

APRE$0

SKYE$143K

Net Cash/Debt

APRE$41M

SKYE$8M

Current Ratio (TTM)

APRE13.55x

SKYE0.95x

Quick Ratio (TTM)

APRE13.33x

SKYE0.91x

Debt/Equity (TTM)

APRE0.00x

SKYE0.03x

Debt/Assets (TTM)

APRE0.0%

SKYE0.0%

Interest Coverage (TTM)

APREN/A

SKYEN/A

Net Debt/EBITDA (TTM)

APRE0.00x

SKYE0.00x

Beta

APRE-1.23

SKYE3.13

52W Performance

APRE-57.8%

SKYE-87.7%

YTD Performance

APRE-29.1%

SKYE-75.9%

% from 52W High

APRE-64.2%

SKYE-88.0%

% from 52W Low

APRE10.3%

SKYE12.7%

Asset Turnover (TTM)

APRE0.02x

SKYE1.93x

FCF Yield (TTM)

APRE-162.8%

SKYE-65.4%

Earnings Yield (TTM)

APRE-164.5%

SKYE-85.0%

Dividend Yield (TTM)

APREN/A

SKYEN/A

Rule of 40

APRE-234,395.5

SKYE0.0

EV/GP/RG

APREN/A

SKYEN/A

Ticker research

View APRE research View SKYE research

Metric	APRE Aprea Therapeutics Inc	SKYE Skye Bioscience Inc
Market & Valuation
Market Cap	$7M	$59M
Enterprise Value	$-34M	$51M
Price	$0.60	$1.69
P/E Ratio	N/A	N/A
P/S Ratio	1,438.94x	26.57x
EV/Sales	-6,490.56x	0.00x
EV/EBITDA	0.00x	0.00x
P/B Ratio	0.22x	0.83x
P/FCF Ratio	N/A	N/A
EV/FCF	2.77x	-1.31x
PEG Ratio	N/A	N/A
Forward P/E (NTM)	N/A	N/A
Forward P/S (NTM)	N/A	N/A
Revenue & Growth
Revenue (TTM)	$5K	$0
Revenue Growth (YoY)	-99.4%	N/A
Forward Rev Growth	445.8%	307.4%
Profitability
Gross Margin (TTM)	0.0%	39.3%
Operating Margin (TTM)	0.0%	0.0%
EBITDA Margin (TTM)	-253869.2%	0.0%
Net Margin (TTM)	-236676.9%	0.0%
FCF Margin (TTM)	-234296.2%	N/A
Net Income (TTM)	$-12M	$-50M
FCF (TTM)	$-12M	$-39M
EPS (TTM)	-$0.23	-$10.18
ROE (TTM)	-4630.0%	-21727.0%
ROA (TTM)	-4097.0%	-20179.0%
ROIC (TTM)	-4630.0%	-21675.0%
Financial Health
Cash	$41M	$9M
Debt	$0	$143K
Net Cash/Debt	$41M	$8M
Current Ratio (TTM)	13.55x	0.95x
Quick Ratio (TTM)	13.33x	0.91x
Debt/Equity (TTM)	0.00x	0.03x
Debt/Assets (TTM)	0.0%	0.0%
Interest Coverage (TTM)	N/A	N/A
Net Debt/EBITDA (TTM)	0.00x	0.00x
Performance
Beta	-1.23	3.13
52W Performance	-57.8%	-87.7%
YTD Performance	-29.1%	-75.9%
% from 52W High	-64.2%	-88.0%
% from 52W Low	10.3%	12.7%
Efficiency & Yields
Asset Turnover (TTM)	0.02x	1.93x
FCF Yield (TTM)	-162.8%	-65.4%
Earnings Yield (TTM)	-164.5%	-85.0%
Dividend Yield (TTM)	N/A	N/A
Other
Rule of 40	-234,395.5	0.0
EV/GP/RG	N/A	N/A
Ticker research	View APRE research	View SKYE research

Valuation

P/S Ratio

SKYE

26.57x

APRE

1,438.94x

EV/FCF

SKYE

-1.31x

APRE

2.77x

Growth & revenue

Revenue Growth TTM

APRE

-99.4%

Forward Revenue Growth

APRE

445.8%

SKYE

307.4%

Profitability & performance

Gross Margin

SKYE

39.3%

APRE

0.0%

ROE

APRE

-4630.0%

SKYE

-21727.0%

FCF Yield %

SKYE

-65.4%

APRE

-162.8%

52-Week Performance

APRE

-57.8%

SKYE

-87.7%

Detailed metrics comparison

APRE

Aprea Therapeutics Inc

SKYE

Skye Bioscience Inc

Market Cap

APRE$7M

SKYE$59M

Enterprise Value

APRE$-34M

SKYE$51M

Price

APRE$0.60

SKYE$1.69

P/E Ratio

APREN/A

SKYEN/A

P/S Ratio

APRE1,438.94x

SKYE26.57x

EV/Sales

APRE-6,490.56x

SKYE0.00x

EV/EBITDA

APRE0.00x

SKYE0.00x

P/B Ratio

APRE0.22x

SKYE0.83x

P/FCF Ratio

APREN/A

SKYEN/A

EV/FCF

APRE2.77x

SKYE-1.31x

PEG Ratio

APREN/A

SKYEN/A

Forward P/E (NTM)

APREN/A

SKYEN/A

Forward P/S (NTM)

APREN/A

SKYEN/A

Revenue (TTM)

APRE$5K

SKYE$0

Revenue Growth (YoY)

APRE-99.4%

SKYEN/A

Forward Rev Growth

APRE445.8%

SKYE307.4%

Gross Margin (TTM)

APRE0.0%

SKYE39.3%

Operating Margin (TTM)

APRE0.0%

SKYE0.0%

EBITDA Margin (TTM)

APRE-253869.2%

SKYE0.0%

Net Margin (TTM)

APRE-236676.9%

SKYE0.0%

FCF Margin (TTM)

APRE-234296.2%

SKYEN/A

Net Income (TTM)

APRE$-12M

SKYE$-50M

FCF (TTM)

APRE$-12M

SKYE$-39M

EPS (TTM)

APRE-$0.23

SKYE-$10.18

ROE (TTM)

APRE-4630.0%

SKYE-21727.0%

ROA (TTM)

APRE-4097.0%

SKYE-20179.0%

ROIC (TTM)

APRE-4630.0%

SKYE-21675.0%

Cash

APRE$41M

SKYE$9M

Debt

APRE$0

SKYE$143K

Net Cash/Debt

APRE$41M

SKYE$8M

Current Ratio (TTM)

APRE13.55x

SKYE0.95x

Quick Ratio (TTM)

APRE13.33x

SKYE0.91x

Debt/Equity (TTM)

APRE0.00x

SKYE0.03x

Debt/Assets (TTM)

APRE0.0%

SKYE0.0%

Interest Coverage (TTM)

APREN/A

SKYEN/A

Net Debt/EBITDA (TTM)

APRE0.00x

SKYE0.00x

Beta

APRE-1.23

SKYE3.13

52W Performance

APRE-57.8%

SKYE-87.7%

YTD Performance

APRE-29.1%

SKYE-75.9%

% from 52W High

APRE-64.2%

SKYE-88.0%

% from 52W Low

APRE10.3%

SKYE12.7%

Asset Turnover (TTM)

APRE0.02x

SKYE1.93x

FCF Yield (TTM)

APRE-162.8%

SKYE-65.4%

Earnings Yield (TTM)

APRE-164.5%

SKYE-85.0%

Dividend Yield (TTM)

APREN/A

SKYEN/A

Rule of 40

APRE-234,395.5

SKYE0.0

EV/GP/RG

APREN/A

SKYEN/A

Ticker research

View APRE research View SKYE research

Metric	APRE Aprea Therapeutics Inc	SKYE Skye Bioscience Inc
Market & Valuation
Market Cap	$7M	$59M
Enterprise Value	$-34M	$51M
Price	$0.60	$1.69
P/E Ratio	N/A	N/A
P/S Ratio	1,438.94x	26.57x
EV/Sales	-6,490.56x	0.00x
EV/EBITDA	0.00x	0.00x
P/B Ratio	0.22x	0.83x
P/FCF Ratio	N/A	N/A
EV/FCF	2.77x	-1.31x
PEG Ratio	N/A	N/A
Forward P/E (NTM)	N/A	N/A
Forward P/S (NTM)	N/A	N/A
Revenue & Growth
Revenue (TTM)	$5K	$0
Revenue Growth (YoY)	-99.4%	N/A
Forward Rev Growth	445.8%	307.4%
Profitability
Gross Margin (TTM)	0.0%	39.3%
Operating Margin (TTM)	0.0%	0.0%
EBITDA Margin (TTM)	-253869.2%	0.0%
Net Margin (TTM)	-236676.9%	0.0%
FCF Margin (TTM)	-234296.2%	N/A
Net Income (TTM)	$-12M	$-50M
FCF (TTM)	$-12M	$-39M
EPS (TTM)	-$0.23	-$10.18
ROE (TTM)	-4630.0%	-21727.0%
ROA (TTM)	-4097.0%	-20179.0%
ROIC (TTM)	-4630.0%	-21675.0%
Financial Health
Cash	$41M	$9M
Debt	$0	$143K
Net Cash/Debt	$41M	$8M
Current Ratio (TTM)	13.55x	0.95x
Quick Ratio (TTM)	13.33x	0.91x
Debt/Equity (TTM)	0.00x	0.03x
Debt/Assets (TTM)	0.0%	0.0%
Interest Coverage (TTM)	N/A	N/A
Net Debt/EBITDA (TTM)	0.00x	0.00x
Performance
Beta	-1.23	3.13
52W Performance	-57.8%	-87.7%
YTD Performance	-29.1%	-75.9%
% from 52W High	-64.2%	-88.0%
% from 52W Low	10.3%	12.7%
Efficiency & Yields
Asset Turnover (TTM)	0.02x	1.93x
FCF Yield (TTM)	-162.8%	-65.4%
Earnings Yield (TTM)	-164.5%	-85.0%
Dividend Yield (TTM)	N/A	N/A
Other
Rule of 40	-234,395.5	0.0
EV/GP/RG	N/A	N/A
Ticker research	View APRE research	View SKYE research